Apimeds Pharmaceuticals Us, Stock Net Asset
| APUS Stock | 1.93 0.05 2.53% |
Fundamental analysis of Apimeds Pharmaceuticals allows traders to better anticipate movements in Apimeds Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Apimeds Pharmaceuticals US, Company Net Asset Analysis
Apimeds Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Apimeds Pharmaceuticals Net Asset | 13.06 K |
Most of Apimeds Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apimeds Pharmaceuticals US, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Apimeds Pharmaceuticals US, has a Net Asset of 13.06 K. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Specialty & Generic industry. The net asset for all United States stocks is notably lower than that of the firm.
Apimeds Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Apimeds Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Apimeds Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apimeds Pharmaceuticals by comparing valuation metrics of similar companies.Apimeds Pharmaceuticals is currently under evaluation in net asset category among its peers.
Apimeds Fundamentals
| Return On Asset | -4.09 | ||||
| Current Valuation | 21.11 M | ||||
| Shares Outstanding | 11.58 M | ||||
| Shares Owned By Insiders | 81.96 % | ||||
| Number Of Shares Shorted | 3.22 K | ||||
| EBITDA | (1.27 M) | ||||
| Net Income | (1.39 M) | ||||
| Total Debt | 596.84 K | ||||
| Book Value Per Share | (0.22) X | ||||
| Cash Flow From Operations | (733.53 K) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (0.13) X | ||||
| Market Capitalization | 24.31 M | ||||
| Total Asset | 13.06 K | ||||
| Retained Earnings | (4.39 M) | ||||
| Working Capital | (1.01 M) | ||||
| Net Asset | 13.06 K |
About Apimeds Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apimeds Pharmaceuticals US,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apimeds Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apimeds Pharmaceuticals US, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.